Last reviewed · How we verify

TAK-875 and Sitagliptin

Takeda · Phase 2 active Small molecule

TAK-875 and Sitagliptin is a Small molecule drug developed by Takeda. It is currently in Phase 2 development. Also known as: Januvia.

At a glance

Generic nameTAK-875 and Sitagliptin
Also known asJanuvia
SponsorTakeda
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about TAK-875 and Sitagliptin

What is TAK-875 and Sitagliptin?

TAK-875 and Sitagliptin is a Small molecule drug developed by Takeda.

Who makes TAK-875 and Sitagliptin?

TAK-875 and Sitagliptin is developed by Takeda (see full Takeda pipeline at /company/takeda).

Is TAK-875 and Sitagliptin also known as anything else?

TAK-875 and Sitagliptin is also known as Januvia.

What development phase is TAK-875 and Sitagliptin in?

TAK-875 and Sitagliptin is in Phase 2.

Related